Actionable news
All posts from Actionable news
Actionable news in GWPH: GW Pharmaceuticals Plc,

GW Pharmaceuticals (GWPH) Stock Gains on Buyout Rumors

GW Pharmaceuticals plc’s GWPH shares gained 23.6% after Reuters published a report that many drugmakers have approached the company for a potential acquisition. GW Pharma has hired investment bank, Morgan Stanley MS, for managing the proposals.

However, both GW Pharma and Morgan Stanley have refused to comment and the prospective buyers remain unidentified.

What Makes GW Pharma a Promising Acquisition Target?

UK-based GW Pharma is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics from its proprietary cannabinoid product platform across a broad range of disease areas. Currently, the company has one marketed product in its portfolio, Sativex, which is approved outside the U.S. for the treatment of spasticity associated with multiple sclerosis.

Companies could be interested in a buyout because of GW Pharma’s lead cannabinoid candidate, Epidiolex, a liquid formulation of pure plant-derived cannabidiol. Epidiolex is currently in phase III development for the treatment of several indications including Dravet syndrome, Lennox-Gastaut syndrome (LGS) and tuberous sclerosis complex.

On its third-quarter fiscal 2016 conference...